Valo Therapeutics has secured €19 million in funding from European and Australian investors to advance its PeptiCRAd cancer immunotherapy platform through Phase 1B clinical trials in Italy, Australia, and Germany.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.